Lumos Pharma (NASDAQ:), a biopharmaceutical company, detailed their progression towards a Phase 3 trial for LUM-201, an oral treatment for pediatric growth hormone deficiency (PGHD), in their first quarter 2024 earnings call. The company has completed a constructive End-of-Phase 2 Meeting with the FDA and is planning to initiate a Phase 3 trial by the end of 2024. They reported $23.2 million in cash reserves at the end of Q1 2024, which is expected to fund operations into the third quarter…
Read More…
Category: Pharma
340B Litigation Update for May 7 Through May 13, 2024
Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary of relevant updates from the prior week in this industry-shaping body of litigation.
Issues at Stake: Contract Pharmacy; Other
In two related cases regarding a state law governing contract pharmacy arrangements, defendant state attorney…
Read More…
Source: https://natlawreview.com/article/week-340b-may-7-may-13-2024?amp
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze – MarketWatch
Mizuho still recommends Terns Pharma as a cheap entry to the weight-loss-drug craze MarketWatchTerns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates Yahoo Finance
Read More…
Consumers Overwhelmingly Open to Receiving New Clinical Services From Pharmacists—Seen as Trusted Healthcare Decision-Makers
ORLANDO, Fla., May 15, 2024–(BUSINESS WIRE)–The vast majority (86%) of consumers are open to receiving new clinical services in pharmacies beyond traditional prescription filling, according to a recent survey commissioned by Outcomes Operating, Inc., an industry expert for integrated pharmacy workflow and patient engagement solutions. Additionally, 83% of respondents said they place a moderately high to very high degree of trust in pharmacists’ decision-making and recommendations about…
Read More…
Source: https://finance.yahoo.com/news/outcomes-survey-consumers-overwhelmingly-open-131500405.html
Digital Pharmaceutical Supply Chain Market 2024 Exclusive Report by InsightAce Analytic
Copyright 2024 PR Newswire. All Rights Reserved2024-05-15
JERSEY CITY, N.J., May 15, 2024 /PRNewswire/ — InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Digital Pharmaceutical Supply Chain Market Size, Share & Trends Analysis Report By Product (Software, Hardware), By Mode Of Delivery (Cloud-based, Web-based, and On -premises), By Software Modules (Software Modules Planning & Analytics, Procurement, Manufacturing, Logistics, and Inventory…
Read More…
TGA issues SSSI for abatacept | AJP – Australian Journal of Pharmacy
TGA issues SSSI for abatacept | AJP Australian Journal of Pharmacy
Read More…
Source: https://ajp.com.au/news/pharmacy-announcements/tga-issues-sssi-for-abatacept/
Sun Pharmaceutical Industries Share Price Today Live Updates: Sun Pharma’s Stock Sees 1.12% Decline Today, 6-Month Returns Stand at 36.5%
08:51:36 AM IST, 15 May 2024Sun Pharmaceutical Industries Share Price Today Live Updates: Sun Pharma Ends at Rs 1525.05 with Lower-than-Average Trading VolumeSun Pharmaceutical Industries closed at Rs 1525.05 yesterday with a trading volume of 2,206,236 shares, slightly below the 7-day average volume of 4,375,275 shares.
Read More…
Pike Co. pharmacy closing after 24 years
Weekday broadcast of WYMT Mountain News First at FourPIKEVILLE, Ky. (WYMT) – Pharmacy runs in the family for Joel Thornburny.The third-generation pharmacist has been working to connect communities with medicine, resources and information for decades.That mission to impact communities brought NOVA pharmacy to Pikeville in 2000. Since then, Thornbury, his partners and his employees have spent decades cultivating a community of care.“They come in and they lay their lives in our hands, and…
Read More…
Source: https://www.wymt.com/2024/05/15/pike-co-pharmacy-closing-after-24-years/?outputType=amp
David Abrams Exits Teva Pharmaceutical in Q1 2024, Reflecting St
Insights into Abrams Capital Management’s Latest 13F Filings David Abrams (Trades, Portfolio), the founder and CEO of Abrams Capital Management, has a notable track record in value investing, honed under the mentorship of Seth Klarman (Trades, Portfolio) at Baupost. Since starting his own firm in 1999, Abrams has adhered to a value-oriented investment philosophy, focusing on long-term, fundamental analysis across a diverse range of assets. The first quarter of 2024 has seen significant…
Read More…
Employer-focused pharmacy benefits company Truveris raises $15M
Truveris, a health technology company focused on decreasing prescription costs for employers and their members, announced it secured $15 million in Series E investment.
Existing investors Canaan Partners and New Leaf Venture Partners led the round.
WHAT IT DOES
The company provides technology to help employers secure lower drug pricing plans. Its software also allows sponsors to garner data-driven insights to reduce prescription costs, improve pharmacy benefit manager contract terms…
Read More…
Source: https://www.mobihealthnews.com/news/employer-focused-pharmacy-benefits-company-truveris-raises-15m